Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

@article{Krejcik2017MonocytesAG,
  title={Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.},
  author={Jakub Krejcik and Kris A Frerichs and Inger S. Nijhof and Berris van Kessel and Jeroen van Velzen and Andries C. Bloem and Marloes E C Broekmans and Sonja Zweegman and Johan van Meerloo and Ren{\'e} J. P. Musters and Pino J. Poddighe and Richard W. J. Groen and Christopher Chiu and Torben Plesner and Henk M. Lokhorst and A. Kate Sasser and Tuna Mutis and Niels W C J van de Donk},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 24},
  pages={
          7498-7511
        }
}
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction.Experimental Design: We evaluated the effect of daratumumab alone or in combination with lenalidomide-dexamethasone, on CD38 levels of multiple myeloma cells and nontumor immune cells in the GEN501 study (daratumumab monotherapy) and the GEN503 study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS